Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Momentum
Price
Neutral
Earnings
Neutral
Growth
Earnings
Neutral
Dividends
Very Strong
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Strong
Website
Opthea LimitedTelephone
61.3.9826.0399
Address
Level 4 Suite 0403 650 Chapel Street South Yarra, Victoria (VIC) 3141
Description
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.34 - 0.95
Trade Value (12mth)
US$258,193.00
1 week
-1.4%
1 month
-13.5%
YTD
35.47%
1 year
54.63%
All time high
3.60
EPS 3 yr Growth
180.90%
EBITDA Margin
%
Operating Cashflow
-$161m
Free Cash Flow Return
-275.90%
ROIC
-377.40%
Interest Coverage
-6.30
Quick Ratio
2.90
Shares on Issue (Fully Dilluted)
679m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
USD
Short Sell (% of issue)
1.17
Date | Announcements |
---|---|
26 November 24 |
Opthea's Wet AMD Program to be Featured at FLORetina 2024
×
Opthea's Wet AMD Program to be Featured at FLORetina 2024 |
25 November 24 |
Opthea Participate in Citi 2024 Global Healthcare Conference
×
Opthea Participate in Citi 2024 Global Healthcare Conference |
15 November 24 |
Chair's Address to Shareholders
×
Chair's Address to Shareholders |
15 November 24 |
Director Appointment/Resignation
×
Director Appointment/Resignation |
15 November 24 |
Results of Meeting
×
Results of Meeting |
15 November 24 |
Opthea Received A$15.9 Million R&D Tax Incentive
×
Opthea Received A$15.9 Million R&D Tax Incentive |
15 November 24 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
12 November 24 |
Opthea's Wet AMD Program Featured at Ophthalmology Events
×
Opthea's Wet AMD Program Featured at Ophthalmology Events |
04 November 24 |
Opthea to Participate in November Investor Conferences
×
Opthea to Participate in November Investor Conferences |
04 November 24 |
Update Opthea Participates in November Investor Conferences
×
Update Opthea Participates in November Investor Conferences |
31 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 October 24 |
Opthea Corporate Presentation - Oct 2024
×
Opthea Corporate Presentation - Oct 2024 |
16 October 24 |
Opthea Files Notice of Annual General Meeting
×
Opthea Files Notice of Annual General Meeting |
16 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
10 October 24 |
Opthea Wet AMD Program to be Presented at Innovate Retina
×
Opthea Wet AMD Program to be Presented at Innovate Retina |
08 October 24 |
Opthea Appoints Chief Medical and Chief Financial Officer
×
Opthea Appoints Chief Medical and Chief Financial Officer |
04 October 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
01 October 24 |
Opthea to participate in UBS Virtual Ophthalmology Day 2024
×
Opthea to participate in UBS Virtual Ophthalmology Day 2024 |
26 September 24 |
Opthea EURetina Symposium 2024
×
Opthea EURetina Symposium 2024 |
23 September 24 |
Opthea Joins the S&P/ASX 300 Index
×
Opthea Joins the S&P/ASX 300 Index |
19 September 24 |
Opthea Announces Completion of Drug Substance Campaign
×
Opthea Announces Completion of Drug Substance Campaign |
11 September 24 |
Opthea Presents at the 24th EURETINA Congress
×
Opthea Presents at the 24th EURETINA Congress |
09 September 24 |
Opthea Corporate Presentation - September 2024
×
Opthea Corporate Presentation - September 2024 |
06 September 24 |
S&P DJI Announces September 2024 Quarterly Rebalance
×
S&P DJI Announces September 2024 Quarterly Rebalance |
05 September 24 |
Opthea Announces Executive Leadership Changes & Senior Hires
×
Opthea Announces Executive Leadership Changes & Senior Hires |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.